ABC Platform Leverage Alector's ABC brain carrier platform to offer partnership opportunities that enhance delivery of CNS therapies, including antibodies, enzymes, and siRNA, to pharma sponsors seeking robust CNS delivery solutions.

Pipeline Focus Target collaborations around ABC-enabled programs such as AL037/AL137 for Alzheimer's, AL050 for Parkinson's, and tau/alpha-synuclein siRNA programs to align with partners pursuing disease-modifying neurodegenerative therapies.

Late-Stage Expertise Position Alector as a value-added partner for late-stage development and potential co-development opportunities, highlighting their near-term readouts and focus on de-risked, genetically validated targets.

Strategic Discontinuation Monetize learnings from the PROGRESS-AD trial discontinuation by offering advisory, biomarker strategies, and translational services to companies needing guidance on phase transitions, trial design, or alternative endpoints.

Neurodegenerative Focus Offer complementary services or collaborations in toxic protein clearance, deficient protein replacement, and immune/neural restoration concepts, aligning with Alector’s mission to counteract neurodegenerative progression and expand therapeutic modalities.